Keyphrases
Adverse Events
21%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
25%
Anaplastic Large Cell Lymphoma
15%
B-cell Lymphoma
18%
Bleomycin
15%
Brentuximab Vedotin
69%
CD30
18%
Chemotherapy
46%
Chimeric Antigen Receptor T Cells (CAR-T)
16%
Chronic Lymphocytic Leukemia
26%
Classical Hodgkin Lymphoma
41%
Clinical Trials
20%
Complete Remission
15%
Complete Response
21%
Confidence Interval
31%
Cyclophosphamide
20%
Diffuse Large B-cell Lymphoma (DLBCL)
58%
Doxorubicin
36%
Etoposide
15%
Follicular Lymphoma
54%
Hazard Ratio
17%
Hodgkin Lymphoma
77%
Ibrutinib
26%
Large B-cell Lymphoma
18%
Lenalidomide
28%
Leukemia
16%
Lymphoma
27%
Lymphoma Patients
20%
Mantle Cell Lymphoma
25%
Mosunetuzumab
16%
NCCN Guidelines
14%
Neutropenia
15%
Non-Hodgkin Lymphoma
39%
Older Patients
18%
Overall Response Rate
23%
Overall Survival
41%
Peripheral T-cell Lymphoma
16%
Phase II Study
41%
Phase II Trial
24%
Positron Emission Tomography
17%
Prednisone
21%
Previously Untreated
16%
Progression-free Survival
59%
Radiation Therapy
15%
Refractory Hodgkin Lymphoma
16%
Relapsed Lymphoma
34%
Relapsed or Refractory
96%
Rituximab
72%
Thrombocytopenia
14%
Vinblastine
16%
Medicine and Dentistry
Adriamycin Bleomycin Vinblastine Dacarbazine
27%
Adverse Event
21%
Anaplastic Large Cell Lymphoma
12%
Arm
23%
Autologous Stem Cell Transplantation
10%
Axicabtagene Ciloleucel
10%
B Cell
17%
B-Cell Chronic Lymphocytic Leukemia
22%
B-Cell Lymphoma
23%
Bendamustine
18%
Brentuximab Vedotin
54%
Chimeric Antigen Receptor T-Cell
10%
Chimeric Antigen Receptor T-Cell Immunotherapy
13%
Classical Hodgkin Lymphoma
46%
Clinical Trial
29%
Cyclophosphamide
18%
Cytokine Release Syndrome
10%
Diffuse Large B-Cell Lymphoma
51%
Diseases
47%
Doxorubicin
29%
Follicular Lymphoma
38%
Hazard Ratio
13%
Hodgkin's Lymphoma
100%
Ibrutinib
23%
Immunotherapy
10%
Large-Cell Lymphoma
22%
Lenalidomide
19%
Leukemia
11%
Malignant Neoplasm
19%
Mantle Cell Lymphoma
23%
Monoclonal Antibody
10%
Mosunetuzumab
11%
Neoplasm
22%
Neutropenia
10%
Non-Hodgkin Lymphoma
41%
Oncology
21%
Overall Survival
45%
Peripheral T-Cell Lymphoma
13%
Polyethylene Terephthalate
12%
Positron Emission Tomography
22%
Prednisone
16%
Prognostic Factor
11%
Progression Free Survival
58%
Radiation Therapy
26%
Rituximab
61%
Stem Cell Transplant
11%
T Cell
10%
Transplantation
17%
Vinblastine
11%
Vincristine
13%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
30%
Anaplastic Large Cell Lymphoma
15%
Antibody Drug Conjugate
9%
B Cell Lymphoma
18%
Bendamustine
19%
Bispecific Antibody
8%
Bleomycin
9%
Bortezomib
10%
Brentuximab Vedotin
52%
Chemotherapy
51%
Chimeric Antigen Receptor
14%
Chronic Lymphatic Leukemia
15%
Classical Hodgkin Lymphoma
22%
Clinical Trial
22%
Cyclophosphamide
21%
Cytokine Release Syndrome
11%
Dacarbazine
9%
Diffuse Large B Cell Lymphoma
46%
Diseases
37%
Doxorubicin
39%
Etoposide
13%
Follicular Lymphoma
47%
Hodgkin Disease
64%
Ibritumomab Tiuxetan
13%
Ibrutinib
18%
Immunotherapy
12%
Large Cell Lymphoma
14%
Lenalidomide
27%
Leukemia
14%
Malignant Neoplasm
21%
Mantle Cell Lymphoma
18%
Maximum Tolerated Dose
8%
Mosunetuzumab
13%
Neoplasm
18%
Neutropenia
13%
Nonhodgkin Lymphoma
57%
Overall Survival
38%
Peripheral T Cell Lymphoma
12%
Phase II Trials
13%
Placebo
10%
Polyethylene Terephthalate
10%
Prednisone
17%
Progression Free Survival
51%
Remission
27%
Rituximab
73%
Survival Rate
10%
Thrombocytopenia
12%
Tolerability
9%
Vinblastine
10%
Vincristine
18%